Thermo Fisher Scientific Inc. $TMO Shares Sold by Formuepleje A S

Key Points

• Formuepleje A S reduced its Thermo Fisher Scientific stake by 6.9% in the second quarter, selling 9,246 shares. The fund still held 125,121 shares worth approximately $62.7 million, representing 4.9% of its portfolio.
• Thermo Fisher reported strong quarterly results, with earnings of $6.03 per share and revenue of $11.99 billion, exceeding analyst estimates. Revenue rose 10.5% year over year, and the company maintained fiscal 2026 EPS guidance of $24.93–$25.33.
• The stock opened at $612.75, near the analyst consensus price target of $619.41, while analysts maintained an overall “Moderate Buy” rating. The company also declared a quarterly dividend of $0.47 per share, producing a 0.3% annualized yield.

Formuepleje A S cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 125,121 shares of the medical research company's stock after selling 9,246 shares during the period. Thermo Fisher Scientific accounts for about 4.9% of Formuepleje A S's portfolio, making the stock its 7th largest holding. Formuepleje A S's holdings in Thermo Fisher Scientific were worth $62,731,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TMO. Legacy Wealth Managment LLC ID lifted its stake in shares of Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after purchasing an additional 22 shares during the last quarter. Kilter Group LLC purchased a new stake in Thermo Fisher Scientific in the 2nd quarter valued at about $25,000. Allied Private Wealth LLC acquired a new position in Thermo Fisher Scientific in the second quarter valued at about $26,000. High Note Wealth LLC boosted its stake in Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock worth $27,000 after buying an additional 29 shares during the period. Finally, Swiss RE Ltd. acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at about $28,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Activity

In other news, VP Lisa P. Britt sold 11,440 shares of the firm's stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the sale, the vice president owned 14,784 shares of the company's stock, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Gianluca Pettiti sold 400 shares of the business's stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the sale, the chief operating officer owned 24,651 shares of the company's stock, valued at approximately $13,927,815. The trade was a 1.60% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 73,768 shares of company stock valued at $44,122,820. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $612.75 on Monday. The stock has a 50-day simple moving average of $570.91 and a 200-day simple moving average of $515.17. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $647.00. The stock has a market capitalization of $226.56 billion, a PE ratio of 32.96, a PEG ratio of 2.57 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion for the quarter, compared to analysts' expectations of $11.71 billion. During the same quarter last year, the company earned $4.28 earnings per share. The firm's revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, analysts predict that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific's payout ratio is 10.11%.

Analysts Set New Price Targets

A number of research firms recently weighed in on TMO. Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. Sanford C. Bernstein started coverage on Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a "market perform" rating and a $520.00 price objective for the company. Stifel Nicolaus set a $650.00 target price on Thermo Fisher Scientific in a research note on Wednesday, August 5th. Royal Bank Of Canada raised their target price on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a report on Friday, July 24th. Finally, Weiss Ratings upgraded shares of Thermo Fisher Scientific from a "hold (c)" rating to a "hold (c+)" rating in a research note on Friday, August 28th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.